Patent · US Active

Humanized affinity matured anti-FcRn antibodies

US10626175B2 · kind B2 · utility

0Cited by

0References

2Claims

0Family size

Assignee

Syntimmune, Inc. · US

Inventors

Laurence J. Blumberg · New York, US
Richard S. Blumberg · Sharon, US
Susan Dana Jones · Boston, US
Derry Roopenian · Salsbury Cove, US
Robert George Edward Holgate · Royston, GB
Timothy David Jones · Babraham, GB
Arron Hearn · Ely, GB

Key dates

Filing date	Nov 13, 2017
Grant date	Apr 21, 2020
Priority date	—
Expiry date	Apr 17, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.